Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 3/20 | 0.45 |
| ▸ | CHUK | O15111 | 3/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | KDM5A | P29375 | 1/20 | 0.44 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.44 |
| ▸ | CDK9 | P50750 | 14/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 13/20 | 0.44 |
| ▸ | CIT | O14578 | 1/20 | 0.42 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16908237 | 0.76 | CCNK (0.44) | IKBKBCHUKCIT | |
| SCHEMBL13012889 | 0.74 | CDK9 (0.49) | IKBKBCHUKCYP2C9CDK9CCNT1 | |
| SCHEMBL1431165 | 0.74 | IKBKB (0.46) | IKBKBCHUKCYP2C9CDK9CCNT1 | |
| SCHEMBL3411433 | 0.74 | CDK9 (0.52) | IKBKBCHUKCYP2C9CDK9CCNT1 | |
| SCHEMBL30380981 | 0.74 | CDK9 (0.52) | IKBKBCHUKCYP2C9CDK9CCNT1 | |
| SCHEMBL16908342 | 0.74 | CHUK (0.44) | IKBKBCHUKKDM5AKDM5BCIT | |
| SCHEMBL3412546 | 0.74 | IKBKB (0.46) | IKBKBCHUKCYP2C9CDK9CCNT1 | |
| SCHEMBL17679777 | 0.72 | CCNK (0.36) | IKBKBCHUKCIT | |
| SCHEMBL16908324 | 0.72 | CIT (0.42) | IKBKBCHUKCIT | |
| SCHEMBL19880896 | 0.72 | CHUK (0.34) | IKBKBCHUKCIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2900666-B1 | AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | CANCER RESEARCH TECH LTD (GB) | 2020-11-04 | — | — | EP | disclosed |
| US-9914730-B2 | Azaquinazoline inhibitors of Atypical protein Kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-03-13 | — | — | US | disclosed |
| US-9914730-B2 | Azaquinazoline inhibitors of Atypical protein Kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-03-13 | — | — | US | disclosed |
| US-9896446-B2 | Azaquinazoline inhibitors of atypical protein kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-02-20 | — | — | US | disclosed |
| US-9896446-B2 | Azaquinazoline inhibitors of atypical protein kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-02-20 | — | — | US | disclosed |
| US-20160102094-A1 | Azaquinazoline Inhibitors of Atypical Protein Kinase C | IGNYTA, INC. (US) | 2016-04-14 | — | — | US | disclosed |
| US-20160102094-A1 | Azaquinazoline Inhibitors of Atypical Protein Kinase C | IGNYTA, INC. (US) | 2016-04-14 | — | — | US | disclosed |
| WO-2014052699-A9 | AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | IGNYTA, INC. (US) | 2015-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102094-A1 | Azaquinazoline Inhibitors of Atypical Protein Kinase C | PRKCQ, PRKCZ, PRKCE | IKBKB 636/4885CHUK 266/4885CYP2C9 4752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.